Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 4.47 CAD -4.89%
Market Cap: 205.5m CAD

Theratechnologies Inc
Accounts Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Theratechnologies Inc
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Theratechnologies Inc
TSX:TH
Accounts Receivables
$11m
CAGR 3-Years
-4%
CAGR 5-Years
-2%
CAGR 10-Years
13%
Repare Therapeutics Inc
NASDAQ:RPTX
Accounts Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Accounts Receivables
$30.7m
CAGR 3-Years
-10%
CAGR 5-Years
95%
CAGR 10-Years
77%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Accounts Receivables
$812k
CAGR 3-Years
-31%
CAGR 5-Years
-13%
CAGR 10-Years
10%
Willow Biosciences Inc
TSX:WLLW
Accounts Receivables
CA$7k
CAGR 3-Years
-59%
CAGR 5-Years
-59%
CAGR 10-Years
N/A
Spectral Medical Inc
TSX:EDT
Accounts Receivables
CA$306k
CAGR 3-Years
45%
CAGR 5-Years
-5%
CAGR 10-Years
-9%
No Stocks Found

Theratechnologies Inc
Glance View

Market Cap
205.5m CAD
Industry
Biotechnology

Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).

TH Intrinsic Value
6.06 CAD
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Theratechnologies Inc's Accounts Receivables?
Accounts Receivables
11m USD

Based on the financial report for May 31, 2025, Theratechnologies Inc's Accounts Receivables amounts to 11m USD.

What is Theratechnologies Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
13%

Over the last year, the Accounts Receivables growth was -14%. The average annual Accounts Receivables growth rates for Theratechnologies Inc have been -4% over the past three years , -2% over the past five years , and 13% over the past ten years .

Back to Top